NEW YORK – Revolution Medicines on Saturday presented data on the preliminary activity of RMC-4630 in combination with cobimetinib (Genentech/Exelixis' Cotellic) in KRAS-mutated colorectal cancer, and said that it will study its SHP2 inhibitor in combination with a drug being advanced by AstraZeneca.